Article
Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.
PloS one - 1 Jan 2014
Zhang Yaxiong, Sheng Jin, Kang Shiyang, Fang Wenfeng, Yan Yue, Hu Zhihuang, Hong Shaodong, Wu Xuan, Qin Tao, Liang Wenhua, Zhang Li
Abstract excerpt
BACKGROUNDS: It has been extensively proved that the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is superior to that of cytotoxic chemotherapy in advanced non-small cell lung cancer (NSCLC) patients harboring sensitive EGFR mutations. However, the question of whether the efficacy of EGFR-TKIs differs between exon 19 deletion and exon 21 L858R mutation has not been yet...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.